tgAAV-CF gene therapy - Targeted Genetics
Alternative Names: tgAAV2-CF; tgAAVCFLatest Information Update: 24 Sep 2021
Price :
$50 *
At a glance
- Originator Targeted Genetics Corporation
- Class Gene therapies
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis